AstraZeneca PLC (NASDAQ:AZN) Stock Position Increased by Gallacher Capital Management LLC

Gallacher Capital Management LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,431 shares of the company’s stock after buying an additional 150 shares during the quarter. Gallacher Capital Management LLC’s holdings in AstraZeneca were worth $368,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Anchor Investment Management LLC acquired a new position in shares of AstraZeneca in the 4th quarter worth $26,000. Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca during the 4th quarter worth about $27,000. Able Wealth Management LLC acquired a new position in shares of AstraZeneca in the fourth quarter worth about $27,000. Pin Oak Investment Advisors Inc. increased its position in shares of AstraZeneca by 468.4% in the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares in the last quarter. Finally, Northwest Financial Advisors purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Up 2.1 %

AZN stock traded up $1.65 during trading hours on Friday, hitting $79.59. The company’s stock had a trading volume of 1,443,268 shares, compared to its average volume of 5,395,919. The stock has a 50 day moving average price of $78.11 and a two-hundred day moving average price of $71.07. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $80.86. The company has a market capitalization of $246.77 billion, a PE ratio of 38.21, a price-to-earnings-growth ratio of 1.40 and a beta of 0.45. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.08. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The firm had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $11.92 billion. On average, equities research analysts expect that AstraZeneca PLC will post 4.04 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. BMO Capital Markets lifted their target price on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, April 26th. Argus increased their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, The Goldman Sachs Group began coverage on shares of AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 target price for the company. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has an average rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.